New Clinical Trial: Hemithoracic Irradiation with Proton Therapy in Malignant Pleural Mesothelioma (HIT-Meso)
A new clinical trial has been funded to investigate the use of proton radiotherapy for patients with malignant pleural mesothelioma.
A new clinical trial has been funded to investigate the use of proton radiotherapy for patients with malignant pleural mesothelioma. Proton therapy is expected to reduce radiation exposure to healthy lung tissue and other organs compared with conventional photon radiotherapy, potentially improving overall survival and quality of life. The trial will recruit 148 patients and randomise them to receive either proton radiotherapy or standard of care (chemotherapy, photon radiotherapy for symptom control, or monitoring).
Mesothelioma is a rare but aggressive cancer with poor survival rates. Proton therapy may provide a more targeted treatment, reducing damage to healthy tissues and improving outcomes.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Moving Beyond Morphology: Toward a Morpho‑Molecular Classification of Pleural Mesothelioma
- Comparison of Survival by Multimodal Treatment Regimen Among Malignant Pleural Mesothelioma Patients in an Integrated Health System
- Systemic Treatments for Unresectable Pleural Mesothelioma: A Review of the Literature
- Prognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma
- Tumor Treating Fields (TTFields) for Pleural Mesothelioma